Filing Details

Accession Number:
0001209191-18-034193
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-05-30 17:12:30
Reporting Period:
2018-05-30
Accepted Time:
2018-05-30 17:12:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1659323 Iterum Therapeutics Plc ITRM Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1734033 M. Judith Matthews C/O Iterum Therapeutics Plc, Blk 2
Fl. 3, Harcourt Centre, Harcourt St.
Dublin L2 2
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2018-05-30 10,980 $0.00 46,626 No 4 C Direct
Ordinary Shares Acquisiton 2018-05-30 3,038 $0.00 49,664 No 4 C Direct
Ordinary Shares Acquisiton 2018-05-30 2,466 $0.00 52,130 No 4 C Direct
Ordinary Shares Acquisiton 2018-05-30 4,000 $13.00 56,130 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Series A Preferred Shares Disposition 2018-05-30 10,980 $0.00 10,980 $0.00
Ordinary Shares Series B-1 Preferred Shares Disposition 2018-05-30 3,038 $0.00 3,038 $0.00
Ordinary Shares Series B-2 Preferred Shares Disposition 2018-05-30 2,466 $0.00 2,466 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
  2. The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
  3. The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
  4. Not applicable.